EICHOR
● Not Yet Recruiting
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
Condition: Acute Ischemic Stroke · Sponsor: NeuroTrauma Sciences, LLC
About this study
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
This description comes directly from the study's public registry record.
Talk to the study team
Scott C Oshana, BS · 18603022074 · s.oshana@neurotraumasciences.com
Allison Ward, MSA, MSEd · 910-616-8586 · a.ward@neurotraumasciences.com
Always discuss trial participation with your own doctor first.
Locations (0)
| Locations not yet listed on the registry record. |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07742098